 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| OLX301A / OliX Pharma, Thea Laboratories
New P1 trial: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Dec 8, 2022
P1, N=60, Recruiting, Sponsor: Olix Pharmaceuticals, Inc.